LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN + GALLIUM GA-68 GOZETOTIDE for renal insufficiency

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Aug 2023: Trial registered, NCT06004661
  2. 4 Apr 2024: Trial started, NCT06004661

The trials

NCT06004661: Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

State
Under way
Phase
Phase 2
People
23 taking part
Started
4 Apr 2024
Primary completion
6 Nov 2026
Arms
AAA617
Results
None posted
  1. 22 Aug 2023: Trial registered
  2. 4 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.